Vaccines for Type 1 Diabetes

Chapter
First Online:

Abstract

By primary prevention aimed at avoiding or averting environmental factors thought to promote disease in genetically at-risk individuals T1D would be eradicated ideally, but these factors have not been identified and may be ubiquitous. Since the early 1980s, secondary prevention, after the disease process has started, has been the focus of considerable attention and with many candidate agents, mainly immunosuppressive drugs have been trialled, usually after the onset of clinical diabetes. Prevention is however more applicable to early, preclinical disease rather than to recent onset clinical disease, when beta cell destruction is more advanced. Prevention of the infectious disease by exposing the immune system to the weakened or dead infectious agent has been a traditional vaccination method. Alternate method called “inverse vaccination” (the inhibition of immune response) arrests autoimmunity through manipulation of the innate and adaptive arms of the immune system. Inverse vaccination specifically reduces a pathological adaptive autoimmune response. Targeted reduction of unwanted antibody and T-cell responses to autoantigens is allowed by inverse vaccination, while leaving the remainder of the immune system intact. Varying degree of success in suppression of β-cell autoimmunity in NOD mice have been shown by current options for treatment of autoimmunity such as immunosuppressive drugs (e.g. cyclosporine) and anti T-cell antibodies (e.g. anti-CD3 antibodies). But the drawback with these methods is that it requires repeated administration and may lead to non-specific harmful effects such as interference with normal immune system functions. Whereas, antigen specific immunotherapy (ASI) uses inverse vaccination for a specific auto-antigen. The advantage with the ASI is selective inactivation of auto-reactive T cells without interference in normal immune function. Major examples of antigen specific immunotherapy agent at various stage of clinical trials are alum formulated glutamic acid decarboxylase and heat shock protein and peptide 277.

Keywords

Glutamic Acid Decarboxylase Human Leucocyte Antigen Islet Autoantibody Oral Insulin Intranasal Insulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Cernea, S., Dobreanu, M., Raz, I.: Prevention of type 1 diabetes: today and tomorrow. Diabetes Metab. Res. Rev. 26, 602–605 (2010)PubMedCrossRefGoogle Scholar
  2. 2.
    Harrison, L.C.: The prospect of vaccination to prevent type 1 diabetes. Hum. Vaccin. 1, 143–150 (2005)PubMedCrossRefGoogle Scholar
  3. 3.
    Ludvigsson, J.: The role of immunomodulation therapy in autoimmune diabetes. J. Diabetes Sci. Technol. 3, 320–330 (2009)PubMedGoogle Scholar
  4. 4.
    Appel, S.J., et al.: Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. J. Am. Acad. Nurse Pract. 21, 156–159 (2009)PubMedCrossRefGoogle Scholar
  5. 5.
    Hjorth, M. Immunological profile and aspects of immunotherapy in type 1 diabetes. Linköping University Medical dissertations, vol. 1161 (2010). liu.diva-portal.org/smash/get/diva2:279876/FULLTEXT01. Accessed 26 Aug 2012Google Scholar
  6. 6.
    Raz, I., Eldor, R., Naparstek, Y.: Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol. 23, 128–134 (2005)PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang, L., Eisenbarth, G.S.: Prediction and prevention of type 1 diabetes mellitus. J. Diabetes 3, 48–57 (2011)PubMedCrossRefGoogle Scholar
  8. 8.
    Tian, J., Kaufman, D.L.: Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 58, 1939–1946 (2009)PubMedCrossRefGoogle Scholar
  9. 9.
    Boettler, T., von Herrath, M.: Type 1 diabetes vaccine development: animal models vs. humans. Hum. Vaccin. 7, 19–26 (2011)PubMedCrossRefGoogle Scholar
  10. 10.
    Nicholas, D., Odumosu, O., Langridge, W.H.: Autoantigen based vaccines for type 1 diabetes. Discov. Med. 11, 293–301 (2011)PubMedGoogle Scholar
  11. 11.
    Steinman, L.: Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. J. Intern. Med. 267, 441–451 (2010)PubMedCrossRefGoogle Scholar
  12. 12.
    Petrovsky, N., Silva, D., Schatz, D.A.: Vaccine therapies for the prevention of type 1 diabetes mellitus. Paediatr. Drugs 5, 575–582 (2003)PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta, S.K.: Vaccines for type 1 diabetes in the late stage of clinical development. Indian J. Pharmacol. 43, 485 (2011)PubMedCrossRefGoogle Scholar
  14. 14.
    Sanjeevi, C.B.: Type 1 diabetes research: Newer approaches and exciting developments. Int. J. Diabetes Dev Ctries 29, 49–51 (2009)PubMedCrossRefGoogle Scholar
  15. 15.
    Faustman, D.L., et al.: Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 7, e41756 (2012)PubMedCrossRefGoogle Scholar
  16. 16.
    Clemente-Casares, X., Tsai, S., Huang, C., Santamaria, P.: Antigen-specific therapeutic approaches in type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007773 (2012)PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang, Z.J., Davidson, L., Eisenbarth, G., Weiner, H.L.: Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. U. S. A. 88, 10252–10256 (1991)PubMedCrossRefGoogle Scholar
  18. 18.
    Herold, K.C., et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698 (2002)PubMedCrossRefGoogle Scholar
  19. 19.
    Chatenoud, L., Thervet, E., Primo, J., Bach, J.F.: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 91, 123–127 (1994)PubMedCrossRefGoogle Scholar
  20. 20.
    Bour-Jordan, H., Bluestone, J.A.: B cell depletion: a novel therapy for autoimmune diabetes? J. Clin. Invest. 117, 3642–3645 (2007)PubMedCrossRefGoogle Scholar
  21. 21.
    Pescovitz, M.D., et al.: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143–2152 (2009)PubMedCrossRefGoogle Scholar
  22. 22.
    Huppmann, M., Baumgarten, A., Ziegler, A.G., Bonifacio, E.: Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care 28, 1204–1206 (2005)PubMedCrossRefGoogle Scholar
  23. 23.
    Fischer, B., Elias, D., Bretzel, R.G., Linn, T.: Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update. Expert Opin. Biol. Ther. 10, 265–272 (2010)PubMedCrossRefGoogle Scholar
  24. 24.
    Rewers, M., Gottlieb, P.: Immunotherapy for the prevention and treatment of type 1 diabetes. Diabetes Care 32, 1769–1782 (2009)PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Department of PharmacologyDhanalakshmi Srinivasan Medical College and HospitalSiruvachur, PerambalurIndia

Personalised recommendations